Drugs / Tetanus, diphtheria, and acellular pertussis vaccine
Tetanus, diphtheria, and acellular pertussis vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05028634 | Nov 2021 → Nov 2023 | relapsing-remitting multiple sclerosis | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus, diphtheria, and acellular pertussis vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05028634 ↗ |
| Modality | Vaccine | “Tetanus, diphtheria, and acellular pertussis vaccine” NCT05028634 ↗ |